Ann: US Clinical Trial Results Published, page-29

Very disappointing reaction yesterday however a few things still keep me confident on my large purchase at 20c

- major shareholder added a large amount on the first ann at average 21c
- results were signifcant regardless of how our market reacted, both from a financial point of view for us but also for the sufferers of autism.
- the new improved device is imminent and this will hopefully relieve some resistance seen in the study as it should be more discreet.
- new ceo isn’t just an average ceo, I believe that part happened for a reason...
- yesterday’s selling could’ve been people trapped from the last spike just recently to 24.5 and were only after a short term hold
- with results like that also I wouldn’t be surprised if a left field ann came out from a major to help us out with funding or distribution channels.

I did hope for a better reaction as we all did but just need to reassure the market and hopefully over the next month or two that will shine through.